Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

Six patients with advanced Hodgkin's disease in which multiple conventional treatments (median prior chemotherapy regimens: seven), radiation therapy, and a prior autologous stem cell transplantation (SCT) had failed underwen t allogeneic SCT following a fludarabine-based conditioning regimen. Median age was 29 years (22-30), Median time to progression after autologous SCT was 6 months (4-21), Disease status at transplant was refractory relapse (n = 3) and sensitive relapse (n = 3). Cell source was filgrastim-mobilized p eripheral blood stem cells from an HLA-identical sibling (n = 4) or matched unrelated donor marrow (n = 2), Conditioning regimens were fludarabine-cyc lophosphamide-antithymocyte globulin (n = 4), fludarabine-melphalan (n = 1) and fludarabine-cytarabine-idarubicin (n = 1). Myeloid recovery was prompt , with an absolute neutrophil count greater than or equal to 500/mu l on da y 12 (11-15). Median platelet recovery to greater than or equal to 20000/mu l was on day 9 (0-60). Chimerism studies on day 30 indicated 100% donor-de rived hematopoiesis in 4/5 evaluable patients (4/4 non-progressors). All re sponders (3/3) have ongoing 100% donor-derived chimerism. Acute graft-versu s-host disease (GVHD) was diagnosed in 4/6 evaluable patients. Chronic GVHD was present in 2/4 evaluable patients. There were no regimen-related death s. Overall day 100 transplant-related mortality was 2/6 (33%). Three patien ts have expired and three are alive and progression-free with a median foll ow-up of 9 months (6-26) post transplant. We conclude that allogeneic stem cell transplantation with fludarabine-based preparative regimens is feasibl e in these high-risk, heavily pretreated HD patients.